Study start date: October 1, 1996Actual date on which the first participant was enrolled.
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.
Official TitleEfficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
From 19 to 57 YearsRange of ages for which participants are eligible to join.
Healthy volunteers not allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Narcotic-Related Disorders
Mental Disorders
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Criteria
Please contact site for information.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 1 location
Suspended
University of PennsylvaniaPhiladelphia, United StatesSee the location